Smith & Nephew plc 14.9% Potential Upside Indicated by Jefferies International

Broker Ratings

Smith & Nephew plc with EPIC/TICKER (LON:SN) has had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘BUY’ today by analysts at Jefferies International. Smith & Nephew plc are listed in the Health Care sector within UK Main Market. Jefferies International have set a target price of 2160 GBX on its stock. This would indicate that the analyst believes there is a potential upside of 14.9% from today’s opening price of 1879.5 GBX. Over the last 30 and 90 trading days the company share price has increased 17.5 points and increased 207.5 points respectively. The 1 year high for the stock price is 1998.4 GBX while the 52 week low for the share price is 1402 GBX.

Smith & Nephew plc has a 50 day moving average of 1,779.06 GBX and the 200 Day Moving Average price is recorded at 1,776.30. There are currently 155,242,923 shares in issue with the average daily volume traded being 2,143,708. Market capitalisation for LON:SN is £16,441,293,217 GBP.

Share on:
Find more news, interviews, share price & company profile here for:

    Smith & Nephew Plc delivers Q3 revenue of $1,412 million, 4% growth

    Smith & Nephew's Q3 2024 update shows a 4% revenue growth to $1,412M. Despite China headwinds, US Orthopaedics and Sports Medicine excelled.

    Smith & Nephew Plc transforming into a higher growth and more profitable business

    Smith & Nephew plc (LON:SN, NYSE:SNN) reports a robust financial performance for Q2 and H1 2024, showing significant revenue and profit growth.

    Smith & Nephew Q1 trading update shows revenue growth and confident outlook

    Smith+Nephew plc (LON:SN, NYSE:SNN) reports Q1 revenue of $1,386 million, up 2.9% underlying. Orthopaedics and Sports Medicine show strong growth. CEO confident in outlook.

    Smith & Nephew reports Q4 revenue of $1,458 million, up 6.4%

    Smith+Nephew plc reports solid financial results for Q4 and full year 2023, showcasing growth in revenue and profit margins. Analyst call scheduled for 27 Feb 2024.

    Smith+Nephew to attend AAOS 2024, showcasing leading Orthopaedic solutions

    Smith+Nephew plc (LON:SN, NYSE:SNN) will be attending AAOS 2024 Annual Meeting to showcase its innovative medical technology solutions in San Francisco. Learn about their latest products and updates in the orthopaedic field.

      Search

      Search